Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.

Anthony BuissonStéphane NanceyLuc ManlayDavid T RubinXavier HebuterneBenjamin ParienteMathurin FumeryDavid LaharieXavier RoblinGilles BommelaerBruno PereiraLaurent Peyrin-BirouletLucine Vuittonnull null

Published in: United European gastroenterology journal (2021)

Ustekinumab seemed to be more effective than azathioprine in preventing POR in this cohort of CD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patients undergoing
patient reported outcomes
free survival